Ventyx Biosciences, Inc. Common Stock (VTYX) Stock Price, Quote & AI Analysis
Live VTYX stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Ventyx Biosciences, Inc. Common Stock.
TradeVae provides AI-driven analysis and real-time market intelligence for Ventyx Biosciences, Inc. Common Stock (VTYX), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.
AI Analysis
Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.
Generating AI analysis...
Ventyx Biosciences, Inc. Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.
Ventyx Biosciences, Inc. Common Stock Overview
Company information
Company Overview
Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.
Company Details
Technical Indicators
Key technical analysis metrics and signals
Loading technical indicators...
Valuation Metrics
Key valuation ratios and comparisons
Loading valuation metrics...
Ventyx Biosciences, Inc. Common Stock Earnings & Financial Statements
Earnings Calendar
Upcoming earnings dates and historical surprises
Loading earnings calendar...
Financial Statements
Income statements, balance sheets, and cash flow
Loading income statements...
Loading balance sheets...
Loading cash flow statements...